Cerus Corporation announced record fourth-quarter financial results, with product revenue growing 10% year-over-year to $44.0 million. The company is reiterating its full-year 2023 annual product revenue guidance range of $165 million to $170 million.
Product revenue grew 10% YoY in Q4 2022, reaching $44.0 million.
The increase in product revenue was driven by increased sales of INTERCEPT platelet kits to blood center customers across the U.S.
Product gross profit for the fourth quarter of 2022 was $24.5 million, the highest in the Company’s history, increasing by 20% over the prior year period.
Company reiterates full-year 2023 annual product revenue guidance range of $165 million to $170 million.
The Company expects full-year 2023 product revenue will be in the range of $165-$170 million.
Visualization of income flow from segment revenue to net income